| Name | Fluvoxamine maleate |
| Description | Fluvoxamine maleate (DU-23000 (maleate)) is a selective serotonin reuptake inhibitor that is used in the treatment of depression and a variety of anxiety disorders. |
| In vitro | Fluvoxamine increases [5-HT]ex levels in rat the prefrontal cortex and thalamus, and also increases [DA]ex levels in the striatum. [1] Fluvoxamine maleate ameliorates tactile allodynia via spinal 5-HT2A/2C receptors, by acting on the receptors or 5-HT neurons. [2] |
| In vivo | Fluvoxamine maleate also exhibits the antinociception in a dose-dependent manner in the paw pressure test in non-ligated mice. Fluvoxamine maleate also induces antinociceptive effect in the acute paw pressure test, and this effect is antagonized by the 5-HT3 receptor antagonist granisetron. [2] Fluvoxamine (10 and 30 mg/kg, i.p.) enhances synaptic efficacy in the hippocampo-mPFC pathway in a dose-dependent manner in the rat hippocampo-medial prefrontal cortex (mPFC). [3] Fluvoxamine (10 and 30 mg/kg, i.p.) suppresses long-term potentiation (LTP) in the hippocampal CA1 field of anesthetized rats. Fluvoxamine (30 mg/kg, i.p.)-induced suppression of LTP is completely reversed by the 5-HT(1A) receptor antagonist NAN-190 (0.5 mg/kg, i.p), but not by the 5-HT(4) receptor antagonist GR 113808 (20 mg/rat, i.c.v.) and the 5-HT(7) receptor antagonist DR 4004 (10 mg/rat, i.c.v.). [4] Fluvoxamine maleate reinforces the response to norepinephrine of isolated rat vas deferens incubated in Krebs-Henseleit solution. Fluvoxamine maleate and Fluoxetine hydrochloride inhibit the contraction induced by potassium ion on the isolated rat uterus preparation with IC50 of 3.99 μM and 18.2 μM, respectively. [5] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 250 mg/mL (575.49 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.6 mM), Sonication is recommended.
|
| Keywords | SLC6A4 | SERT | SerotoninTransporter | Serotonin Transporter | MK264 | MK 264 | Inhibitor | inhibit | Fluvoxamine Maleate | Fluvoxamine | DU-23000 | DU23000 | DU 23000 | 5-HTT | 5HTReceptor | 5HT Receptor | 5-HT |
| Inhibitors Related | Alverine citrate | Sevoflurane | Dapoxetine hydrochloride | Cefaclor monohydrate | Clozapine N-Oxide | 1,8-Cineole | Dopamine hydrochloride | Cloperastine hydrochloride | Mianserin hydrochloride | Trazodone hydrochloride | Cinchonidine | Doxepin hydrochloride |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
